{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:01:51Z","timestamp":1784617311064,"version":"3.55.0"},"reference-count":22,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100019211","name":"AbbVie","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2652780","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:31:54Z","timestamp":1777368714000},"page":"1230-1245","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous foslevodopa\/foscarbidopa (LDp\/CDp) in advanced Parkinson\u2019s disease (aPD): societal cost impact analysis for the UK, France, Germany, Spain, and Canada"],"prefix":"10.1080","volume":"29","author":[{"given":"K.","family":"Ray Chaudhuri","sequence":"first","affiliation":[{"name":"Institute of Neuroscience Kings College","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Parra","sequence":"additional","affiliation":[{"name":"AbbVie","place":["Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trishal","family":"Boodhna","sequence":"additional","affiliation":[{"name":"AbbVie","place":["Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7283-327X","authenticated-orcid":false,"given":"Jonathan","family":"Belsey","sequence":"additional","affiliation":[{"name":"JB Medical Ltd","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080952"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch1"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom11040612"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4047392"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23462"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2009.07.015"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-004-6253-y"},{"key":"e_1_3_4_9_1","unstructured":"Gumber A Ramaswamy B Ibbotson R et al. Economic social and financial cost of Parkinson\u2019s on individuals carers and their families in the UK 2017. Available from: https:\/\/shura.shu.ac.uk\/15930\/#:\u223c:text=The%20total%20societal%20cost%20was by%20Parkinson\u2019s%20averages%20%C2%A316%2C582"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-023-00410-1"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.551164"},{"issue":"10","key":"e_1_3_4_12_1","first-page":"S188","article-title":"The economic and societal burden of Alzheimer disease: managed care considerations","volume":"28","author":"Skaria AP.","year":"2022","unstructured":"Skaria AP. The economic and societal burden of Alzheimer disease: managed care considerations. Am J Manag Care. 2022;28(10 Suppl):S188\u2013S196.","journal-title":"Am J Manag Care"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22696"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2400857"},{"key":"e_1_3_4_15_1","unstructured":"National Institute for Health and Care Excellence. Foslevodopa\u2013foscarbidopa for treating advanced Parkinson\u2019s with motor symptoms: TA 934. 2023 Nov. Available from: https:\/\/www.nice.org.uk\/guidance\/ta934"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00400-8"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00533-1"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208722"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802457040"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28727"},{"key":"e_1_3_4_21_1","unstructured":"OECD. Taxing wages 2025. Decomposition of personal income taxes and the role of tax reliefs. Country notes. Available from: https:\/\/www.oecd.org\/en\/publications\/taxing-wages-2025_b3a95829-en\/support-materials.html"},{"key":"e_1_3_4_22_1","unstructured":"PSSRU. Unit costs of Health & Social Care 2024. Available from: https:\/\/kar.kent.ac.uk\/109563\/"},{"key":"e_1_3_4_23_1","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of Parkinson\u2019s disease. 2012. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-parkinsons-disease_en.pdf-0"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2652780","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13696998.2026.2652780","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2652780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:14:26Z","timestamp":1784614466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2652780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2652780"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2652780","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}